NCT01348737View on ClinicalTrials.gov

Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
Alzheimer's DiseaseSafetyTolerabilityBlood ConcentrationHealthy Volunteers
Interventions
DRUG

AZD3839

Single Oral Dose

DRUG

AZD3839 Placebo

Single Oral Dose

Trial Locations (1)

Unknown

Research Site, London

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY